{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:33:02Z","timestamp":1792128782826,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41375-025-02675-7","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T20:49:37Z","timestamp":1751489377000},"page":"2266-2269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1955-0709","authenticated-orcid":false,"given":"Julian","family":"Ronnacker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Ruhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-0548","authenticated-orcid":false,"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2918-2554","authenticated-orcid":false,"given":"Anke","family":"Morgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Unglaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4519-1002","authenticated-orcid":false,"given":"David","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Fransecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie Nogueira","family":"Gezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Crysandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-0804","authenticated-orcid":false,"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-7490","authenticated-orcid":false,"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-2780","authenticated-orcid":false,"given":"Andrew F.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1019-5150","authenticated-orcid":false,"given":"Marc-Andr\u00e9","family":"Urbahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4850-7359","authenticated-orcid":false,"given":"Lina","family":"Kolloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-834X","authenticated-orcid":false,"given":"Claudia","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-3029","authenticated-orcid":false,"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Wethmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utz","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-9583","authenticated-orcid":false,"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2675_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2675_CR2","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392.","journal-title":"J Clin Oncol"},{"key":"2675_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood-2023-189025","volume":"142","author":"F Guolo","year":"2023","unstructured":"Guolo F, Fianchi L, Martelli MP, Chiusolo P, Lussana F, Grimaldi F, et al. Optimal duration of CPX-351 treatment and best timing for consolidation with allogeneic stem cell transplantation: evidence from a large real-world Italian study. Blood. 2023;142:731.","journal-title":"Blood"},{"key":"2675_CR4","doi-asserted-by":"crossref","unstructured":"Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O\u2019Nions J, et al. CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK. Br J Haematol. 2024;205:1326\u201336.","DOI":"10.1111\/bjh.19622"},{"key":"2675_CR5","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1080\/10428194.2021.1907378","volume":"62","author":"LL Benitez","year":"2021","unstructured":"Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, et al. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma. 2021;62:2184\u201392.","journal-title":"Leuk Lymphoma"},{"key":"2675_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01274-0","volume":"15","author":"C Rautenberg","year":"2025","unstructured":"Rautenberg C, Middeke JM, R\u00f6llig C, Stelljes M, Gaidzik V, Kriege O, et al. Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients. Blood Cancer J. 2025;15:60.","journal-title":"Blood Cancer J"},{"key":"2675_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1182\/blood-2002-02-0532","volume":"101","author":"W Kern","year":"2003","unstructured":"Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101:64\u201370.","journal-title":"Blood"},{"key":"2675_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3324\/haematol.2013.091819","volume":"99","author":"S Bertoli","year":"2014","unstructured":"Bertoli S, Bories P, B\u00e9n\u00e9 MC, Daliphard S, Lioure B, Pigneux A, et al. Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. Haematologica. 2014;99:46\u201353.","journal-title":"Haematologica"},{"key":"2675_CR9","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/ajh.24818","volume":"92","author":"CM Terry","year":"2017","unstructured":"Terry CM, Shallis RM, Estey E, Lim SH. Day 14 bone marrow examination in the management of acute myeloid leukemia. Am J Hematol. 2017;92:1079\u201384.","journal-title":"Am J Hematol"},{"key":"2675_CR10","doi-asserted-by":"crossref","unstructured":"Jamy O, Bourne G, Mudd TW, Thigpen H, Bhatia R. Revisiting the Role of Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia. Cancers (Basel). 2025;17:900.","DOI":"10.3390\/cancers17050900"},{"key":"2675_CR11","first-page":"1285","volume":"85","author":"V Liso","year":"2000","unstructured":"Liso V, Albano F, Pastore D, Carluccio P, Mele G, Lamacchia M, et al. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. Haematologica. 2000;85:1285\u201390.","journal-title":"Haematologica"},{"key":"2675_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/ajh.24627","volume":"92","author":"PT Griffin","year":"2017","unstructured":"Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, et al. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017;92:232\u20137.","journal-title":"Am J Hematol"},{"key":"2675_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol F, D\u00f6hner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143:11\u201320.","journal-title":"Blood"},{"key":"2675_CR14","unstructured":"Pollyea DA, Altman JK, Assi R, Bachiashvili K, Bhatt V, Fathi AT, et al. NCCN Guidelines Version 2.2025 Acute Myeloid Leukemia (Age \u226518 years). In: National Comprehensive Cancer Network. 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1411. Accessed 01 July 2025."},{"key":"2675_CR15","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3324\/haematol.2021.279134","volume":"107","author":"J Ihlow","year":"2022","unstructured":"Ihlow J, Gross S, Busack L, Fl\u00f6rcken A, Jesse J, Schwarz M, et al. Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy. Haematologica. 2022;107:1773\u201385.","journal-title":"Haematologica"},{"key":"2675_CR16","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1002\/cncr.25263","volume":"116","author":"JM Rowe","year":"2010","unstructured":"Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010;116:5012\u201321.","journal-title":"Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02675-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02675-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02675-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:38:44Z","timestamp":1757205524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02675-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2675"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02675-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CR received honoraria from AbbVie, Astellas, Bristol-Meyer-Squibb, Daiichi Sankyo, Jazz, Janssen, Novartis, Otsuka, Pfizer, Servier, and institutional research funding from AbbVie, Astellas, Novartis, Pfizer. JMM has served as a consultant for Janssen, Roche, Gilead, Abbvie, JAZZ Pharmaceuticals, Pfizer, Astellas, Novartis, AstraZeneca, Beigene, Glycostem; is a shareholder of Cancilico and Synagen; has received research funding from Servier, Janssen, and Novartis; has received travel support from Beigene. JMU received travel grants from Jazz Pharmaceuticals and AbbVie. TS received honoraria and travel support from Jazz Pharmaceuticals and is part of the advisory board of Jazz Pharmaceuticals. MJ received honoraria from Jazz Pharmaceuticals. AFB received speaker honoraria and travel grant from AbbVie. MH received honoraria from Novartis, Gilead, the Falk Foundation, SOBI, and BMS. MH is consultant for Janssen, Kite, Amgen, Sanofi, BMS, and BeiGene. MH received travel support from Abbvie. MS received grants not related to this manuscript from Pfizer. MS received honoraria not related to this manuscript from Pfizer, Jazz, Amgen, Novartis, Gilead, Celgene, medac, BMS, MSD, Incyte. MB received lecture fees and honoraria for advisory board participation from Jazz Pharmaceuticals and served on advisory boards for Acitrexx and MSD. GL received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. GL received honoraria from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal\/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi. CS received institutional research support not related to this manuscript from Jazz Pharmaceuticals. CS received honoraria not related to this manuscript from AbbVie, Astellas, AstraZeneca, BMS, Laboratories Delbert, Jazz Pharmaceuticals, Novartis, Otsuka, Pfizer, Roche, and travel grants from AbbVie, BMS, Jazz Pharmaceuticals, Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All described methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from participants for inclusion in the clinical AML registry of the SAL (NCT03188874). The study was approved by the local Ethics Committee of Westphalia-Lippe (AZ 2023-032-f-S) as well as by the institutional review board of the SAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}